the Circle. gbxcircle.com · On the record

On the record.In the rooms.

The rooms, in their own words. Recorded on the floor at BILS, DDIF and MEVO, not written afterwards.

We are approaching an age where, with extraordinary data sources and incredible compute, we can begin to understand how DNA dictates protein function. Where we go next is more exciting still. We can program biology in intentional ways, to treat individual diseases.

Dinesh de Alwis

Chief Development Officer · Generate Biomedicines

BILS · bils.ai

Watching loved ones get seriously ill, or live with chronic disease, is the biggest motivator for bringing innovation into medical research and development.

Angela Vollstedt, PhD MBA

Director Global Cell & Gene Therapies Portfolio Management · Novartis

MEVO · meatevo.com

I am a frequent attendee of cultured meat meetings. Frankly, there are now too many. This is my favourite, and it is because it is not one dimensional. There are people here from other industries, and it brings us together with the cell therapy people. There is a lot in common.

Gábor Forgács

Co-Founder and CSO · Fork & Good

DDIF · ddif.ai

The major barrier to AI impact on drug discovery is not our data and not our models. It is no longer improvements in predictability or datasets. It is how we allocate capital and govern our drug discovery pipelines.

Joanna Holbrook

Former Therapy Area Head · Novo Nordisk

“It’s been only three years, but it’s the beginning of a tradition, but more importantly, it’s an experience.”

Lou Cooperhouse · Founder, President and CEO, BlueNalu · MEVO 2025

BILS · bils.ai

It is a smaller event, and it is more intimate. A really nice cross section of technical and business, small company and large pharma. The people here are very much here to learn, and there is a willingness to really lean in and have really interesting conversations.

Jesse McCool, PhD

CEO · GBI Bio

DDIF · ddif.ai

There are only two certain things in life, death and taxes. The third is patents. You are going to lose your patents, and you have to do something about it early. Some companies wait too long, and then they run into these problems.

Harsukh Parmar

Former SVP, Global Head of Research & Early Development · Merck KGaA

MEVO · meatevo.com

It is one of the best cultivated meat events I have been to. It has been a good collection of relevant stakeholders. We had a great time, we had good opportunities to discuss, and I believe many collaborations will come out of this.

Guy Michrowski

Co-Founder and CEO · ProFuse Technology

For the few.

By invitation. By relevance. By room.

request access the Circle